Assessment for Video 3

Assessment Summary

0 of 9 questions completed

Questions:

You have already completed the assessment before. Hence you can not start it again.

Assessment is loading…

You must sign in or sign up to start the assessment.

You must first complete the following:

Results

Assessment complete. Results are being recorded.

Results

0 of 9 questions answered correctly

Your time:

You have reached 0 of 0 point(s), (0)

Answered
Review

Question 1 of 9

1. Question
1 point(s)
Which of the below statements is a result of a study of CTL119 in CLL relapsed/refractory patients previously treated with ibrutinib:
- a. All patients experience neurotoxicity
- b. One patient died of cardiac arrhythmia
- c. No patients experienced cytokine release syndrome
- d. All of the above
Correct

Incorrect
Question 2 of 9

2. Question
1 point(s)
In a study of CTL119 in CLL relapsed/refractory patients previously treated with ibrutinib, the authors concluded all except:
- a. CT119 showed promising activity in patients not achieving CR despite ≥6 months of ibrutinib
- b. At 3 months, the bone marrow remission rate was 94%
- c. These findings compare favorably to prior CART19 cell studies in patients with progressive CLL
- d. Cytokine release syndrome was frequent and severe and commonly required anti-cytokine therapy
Correct

Incorrect
Question 3 of 9

3. Question
1 point(s)
Concurrent ibrutinib administration worsens outcomes and increases toxicity of CAR T-cell therapy in relapsed or refractory CLL:
- a. True
- b. False
Correct

Incorrect
Question 4 of 9

4. Question
1 point(s)
A limitation of use of approved CAR T –cell therapies in treating DLBCL patients is:
- a. They must be administered daily for 5 days
- b. There are strict upper age limits for administration
- c. They are not indicated for the treatment of patients with primary central nervous system lymphoma
- d. They take several hours to infuse
Correct

Incorrect
Question 5 of 9

5. Question
1 point(s)
One “lesson learned” in treating DLBCL patients is:
- a. More advanced disease may correlate with higher risk for cytokine release syndrome
- b. CAR T -cell therapy requires lengthy infusion times
- c. Prior to CAR T therapy because many have had extensive prior treatment
- d. a and c
Correct

Incorrect
Question 6 of 9

6. Question
1 point(s)
Some question(s) that remain concerning treatment of DLBCL patients with CAR T-cell therapy include:
- a. Impact of prior therapy
- b. Prediction of long-term outcomes
- c. Cost of therapy
- d. a and b
Correct

Incorrect
Question 7 of 9

7. Question
1 point(s)
Severity of CRS correlates with all of the following except:
- a. IL6 levels
- b. C-reactive protein
- c. Albumin
- d. Ferritin
Correct

Incorrect
Question 8 of 9

8. Question
1 point(s)
ASBMT cytokine release grading includes:
- a. Fever, rash, arthralgias
- b. Rash, handwriting, hypoxia
- c. Fever, hypoxia, hypotension
- d. Hypoxia, rash, and elevated C reactive protein
Correct

Incorrect
Question 9 of 9

9. Question
1 point(s)
Immune Effector Encephalopathy (ICE) grading differs from CARTOX-10 grading for neurotoxicity by:
- a. Naming (name 3 objects)
- b. Orientation (year, month, city, hospital)
- c. Following commands (e.g. show me two fingers)
- d. Writing (write a standard sentence)
Correct

Incorrect

Protected: Understanding CAR T-cell Therapy as a Treatment Option for Blood Cancer Patients

Assessment Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question

4. Question

5. Question

6. Question

7. Question

8. Question

9. Question